Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

13-11-2024 | Original Article

Synthesis and preclinical evaluation of [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor

Authors: Haoran Liang, Zihao Chen, Chunwei Mo, Yanjiang Han, Qingxing Liu, Ganghua Tang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2025

Abstract

Purpose

Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11, and compare its preclinical performance with the previously reported antagonist, [¹⁸F]AlF-NOTA-JR11, and the agonist [⁶⁸Ga]Ga-DOTA-TATE.

Methods

[¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 was synthesized via a one-step radiolabeling process involving [¹⁸F]AlF chelation. The binding affinity, internalization, and cellular uptake were evaluated using AR42J/SSTR + cells. Biodistribution and PET/CT imaging were conducted in mice bearing xenografted AR42J/SSTR + or HCT116/SSTR- tumor xenografts.

Results

[¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 was manually synthesized within 30 min with an uncorrected radiochemical yield of 39.56 ± 3.25% (n > 5) and radiochemical purity (RCP) exceeding 99% (n > 5). [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 demonstrated excellent in vivo stability over 2 h (RCP > 95%). Among AR42J cells, [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 exhibited high affinity, specific uptake, and low internalization, similar to [¹⁸F]AlF-NOTA-JR11. Biodistribution and micro-PET/CT imaging studies revealed comparable tumor uptake between [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 and [¹⁸F]AlF-NOTA-JR11 (9.26 ± 0.49 vs. 10.18 ± 0.82%ID/g, p = 0.147) at 60 min post-injection (p.i), both were significantly higher than [⁶⁸Ga]Ga-DOTA-TATE (6.79 ± 0.29%ID/g, p = 0.001). Co-injecting the corresponding inhibitor significantly reduced the tumor uptake of all three tracers. Notably, [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 reached peak tumor uptake at 30 min p.i. and exhibited the lowest uptake and fastest clearance in most normal organs, including the kidney, bone, liver, and muscle, resulting in the highest and increasing tumor-to-background ratios (TBR) over time among the three tracers.

Conclusion

The synthesis of [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 is efficient, with high radiochemical yield and RCP. [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 exhibits excellent in vivo stability, high tumor uptake, and superior TBR, making it a promising potential tracer for imaging SSTR-positive tumors.

Available only for authorised users

Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–88. https://doi.org/10.1111/j.1365-2036.2009.04174.x.CrossRefPubMed

Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–46. https://doi.org/10.1007/s002590100541.CrossRefPubMed

Reubi JC, Waser B, Mäcke H, et al. Highly increased ¹²⁵I-JR11 antagonist binding in Vitro reveals novel indications for sst2 targeting in human cancers. J Nucl Med. 2017;58(2):300–6. https://doi.org/10.2967/jnumed.116.177733v.CrossRefPubMed

Haidar M, Shamseddine A, Panagiotidis E, et al. The role of ⁶⁸Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers. Nucl Med Commun. 2017;38(2):170–7. https://doi.org/10.1097/mnm.0000000000000623.CrossRefPubMed

Barrio M, Czernin J, Fanti S, et al. The impact of somatostatin receptor-Directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and Meta-analysis. J Nucl Med. 2017;58(5):756–61. https://doi.org/10.2967/jnumed.116.185587.CrossRefPubMed

Pauwels E, Cleeren F, Tshibangu T, et al. ¹⁸F-AlF-NOTA-Octreoutperformsrforms ⁶⁸Ga-DOTATATE/NOC Pneuroendocrineotumor patientstiresultsesults fprospectiveective, Multicenter Study. J Nucl Med. 2023;64(4):632–8. https://doi.org/10.2967/jnumed.122.264563.CrossRefPubMed

Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52(9):1412–7. https://doi.org/10.2967/jnumed.111.088922.CrossRefPubMed

Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55(8):1248–52. https://doi.org/10.2967/jnumed.114.138834.CrossRefPubMed

Nicolas GP, Mansi R, McDougall L, et al. Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷Lu-, ⁹⁰Y-, and ¹¹¹In-Labeled somatostatin receptor antagonist OPS201 in comparison to the agonist ¹⁷⁷Lu-DOTATATE: the Mass Effect. J Nucl Med. 2017;58(9):1435–41. https://doi.org/10.2967/jnumed.117.191684.CrossRefPubMed

10.

Rylova SN, Stoykow C, Del Pozzo L, et al. The somatostatin receptor 2 antagonist ⁶⁴Cu-NODAGA-JR11 outperforms ⁶⁴Cu-DOTA-TATE in a mouse xenograft model. PLoS ONE. 2018;13(4):e0195802. https://doi.org/10.1371/journal.pone.0195802.CrossRefPubMedPubMedCentral

11.

Nicolas GP, Schreiter N, Kaul F, et al. Sensitivity comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J Nucl Med. 2018;59(6):915–21. https://doi.org/10.2967/jnumed.117.199760.CrossRefPubMed

12.

Zhu W, Cheng Y, Wang X, et al. Head-to-Head comparison of ⁶⁸Ga-DOTA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: a prospective study. J Nucl Med. 2020;61(6):897–903. https://doi.org/10.2967/jnumed.119.235093.CrossRefPubMedPubMedCentral

13.

Zhu W, Jia R, Yang Q. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with ⁶⁸Ga-DOTATATE. Eur J Nucl Med Mol Imaging. 2022;49(5):1613–22. https://doi.org/10.1007/s00259-021-05512-y.CrossRefPubMed

14.

Lin Z, Zhu W, Zhang J. Head-to-Head comparison of ⁶⁸Ga-NODAGA-JR11 and ⁶⁸Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors: interim analysis of a prospective Bicenter Study. J Nucl Med. 2023;64(9):1406–11. https://doi.org/10.2967/jnumed.122.264890.CrossRefPubMed

15.

Xie Q, Liu T, Ding J, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [¹⁸F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [⁶⁸Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129–40. https://doi.org/10.1007/s00259-021-05249-8.CrossRefPubMed

16.

Hu K, Wang L, Wu H, et al. [¹⁸F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [⁶⁸Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49(8):2833–43. https://doi.org/10.1007/s00259-021-05646-z.CrossRefPubMed

17.

Huang J, Fu L, Hu K, et al. Automatic production and preliminary PET imaging of a New Imaging Agent [¹⁸F]AlF-FAPT. Front Oncol. 2021;11:802676. https://doi.org/10.3389/fonc.2021.802676.CrossRefPubMed

18.

Ogawa K, Ishizaki A, Takai K, et al. Evaluation of Ga-DOTA-(D-Asp)n as bone imaging agents: D-Aspartic acid peptides as carriers to bone. Sci Rep. 2017;7(1):13971. https://doi.org/10.1038/s41598-017-14149-7.CrossRefPubMedPubMedCentral

19.

Kwon D, Zhang Z, Zeisler J, Kuo HT, Lin KS, Benard F. Reducing the kidney uptake of high contrast CXCR4 PET imaging agents via Linker modifications. Pharmaceutics. 2022;14(7):1502. https://doi.org/10.3390/pharmaceutics14071502.CrossRefPubMedPubMedCentral

20.

Wu Z, Li Z, Cai W, He L, Chin F, Li F, et al. ¹⁸F-labeled mini-PEG spacered RGD dimer (¹⁸F-FPRGD2): synthesis and microPET imaging of avβ3 integrin expression. Eur J Nucl Med Mol Imaging. 2007;34(11):1823–31. https://doi.org/10.1007/s00259-007-0427-0.CrossRefPubMedPubMedCentral

21.

Ahenkorah S, Cawthorne C, Murce E, Deroose CM, Cardinaels T, Seimbille Y, Bormans G, Ooms M, Cleeren F. Direct comparison of [¹⁸F]AlF-NOTA-JR11 and [¹⁸F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: antagonist versus agonist. Nucl Med Biol. 2023;118–119108338. https://doi.org/10.1016/j.nucmedbio.2023.108338.

22.

Penchala SC, Miller MR, Pal A, et al. A biomimetic approach for enhancing the in vivo half-life of peptides. Nat Chem Biol. 2015;11(10):793–8. https://doi.org/10.1038/nchembio.1907.CrossRefPubMedPubMedCentral

23.

Chen Q, Meng X, McQuade P, Rubins D, Lin SA, Zeng Z, Haley H, Miller P, González Trotter D, Low PS. Folate-PEG-NOTA-Al¹⁸F: a New Folate based Radiotracer for PET Imaging of Folate receptor-positive tumors. Mol Pharm. 2017;14(12):4353–61. https://doi.org/10.1021/acs.molpharmaceut.7b00415.CrossRefPubMed

24.

Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82. https://doi.org/10.1007/s002590050034.CrossRefPubMed

25.

Cescato R, Erchegyi J, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem. 2008;51(13):4030–7. https://doi.org/10.1021/jm701618q.CrossRefPubMedPubMedCentral

26.

Schottelius M, Šimeček J, Hoffmann F, et al. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE. EJNMMI Res. 2015;5:22. https://doi.org/10.1186/s13550-015-0099-x.CrossRefPubMedPubMedCentral

27.

Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, et al. Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸Ga-OPS202 in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase I imaging study. J Nucl Med. 2018;59(6):909–14. https://doi.org/10.2967/jnumed.117.199737.CrossRefPubMed

28.

Zhu W, Cheng Y, Jia R, Zhao H, Bai C, et al. A prospective, randomized, double-blind study to evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in patients with Well-differentiated neuroendocrine tumors. J Nucl Med. 2021;62(10):1398–405. https://doi.org/10.2967/jnumed.120.253096.CrossRefPubMedPubMedCentral

29.

Rylova SN, Stoykow C, Del Pozzo L, Abiraj K, Tamma ML, Kiefer Y, Fani M, Maecke HR. The somatostatin receptor 2 antagonist ⁶⁴Cu-NODAGA-JR11 outperforms ⁶⁴Cu-DOTA-TATE in a mouse xenograft model. PLoS ONE. 2018;13(4):e0195802. https://doi.org/10.1371/journal.pone.0195802.CrossRefPubMedPubMedCentral

30.

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ. ⁶⁸Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013;40(4):514–23. https://doi.org/10.1007/s00259-012-2309-3.CrossRefPubMed

31.

Dude I, Zhang Z, Rousseau J, Hundal-Jabal N, Colpo N, Merkens H, Lin KS, Bénard F. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharm Chem. 2017;2(1):4. https://doi.org/10.1186/s41181-017-0023-y.CrossRefPubMedPubMedCentral

32.

Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, Waser B, Weber WA, Reubi JC, Maecke HR. PET of somatostatin receptor-positive tumors using ⁶⁴Cu- and ⁶⁸Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52(7):1110–8. https://doi.org/10.2967/jnumed.111.087999.CrossRefPubMed

Title: Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor
Authors: Haoran Liang
Zihao Chen
Chunwei Mo
Yanjiang Han
Qingxing Liu
Ganghua Tang
Publication date: 13-11-2024
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2025
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-024-06978-2

Expert consensus on workflow of PET/CT with long axial field-of-view

Positron Emission Tomography
Guidelines

Long-axial field-of-view PET/CT improves radiomics feature reliability

Original Article

Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard

Glioma
Original Article

Holmium-166 radioembolisation dosimetry in HCC

Open Access
Hepatocellular Carcinoma
Original Article

Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade

Radionuclide Therapy
Original Article

Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T

Open Access
Prostate Cancer
Original Article

Podcast | Sexual health in older age

Springer Medicine

Synthesis and preclinical evaluation of [¹⁸F]AlF-NOTA-Asp₂-PEG₂-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor

Abstract

Purpose

Methods

Results

Conclusion

Other articles of this Issue 3/2025

Expert consensus on workflow of PET/CT with long axial field-of-view

Long-axial field-of-view PET/CT improves radiomics feature reliability

Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard

Holmium-166 radioembolisation dosimetry in HCC

Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade

Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T

Podcast | Sexual health in older age

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Expert consensus on workflow of PET/CT with long axial field-of-view

Long-axial field-of-view PET/CT improves radiomics feature reliability

Individual-level metabolic connectivity from dynamic [18F]FDG PET reveals glioma-induced impairments in brain architecture and offers novel insights beyond the SUVR clinical standard

Holmium-166 radioembolisation dosimetry in HCC

Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade

Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T